12:00 AM
 | 
Jul 30, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Subcutaneous rituximab: Phase III data

Roche reported in its 2Q12 earnings that the open-label, international Phase III SABRINA (BO22334) trial in patients with previously untreated follicular NHL showed that 1,400 mg subcutaneous MabThera plus standard chemotherapy met the Stage 1 primary endpoint of non-inferiority to 375 mg/m 2 IV MabThera plus standard chemotherapy in the ratio of trough serum concentrations of the drug at day 21. Patients are receiving subcutaneous or IV MabThera plus CHOP...

Read the full 329 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >